NRXP

NRX Pharmaceuticals Inc

NRXP, USA

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.

https://www.nrxpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NRXP
stock
NRXP

Holdings of NRX Pharmaceuticals Inc (NRXP) are aligned with the stars setenews.com

Read more →
NRXP
stock
NRXP

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of “Moderate Buy” from Analysts Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$36.5

Analyst Picks

Strong Buy

3

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-1.81

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

22.87 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-39.28 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,194.63 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 16.79% of the total shares of NRX Pharmaceuticals Inc

1.

Anson Funds Management LP

(6.7521%)

since

2025/06/30

2.

Vanguard Group Inc

(1.9023%)

since

2025/06/30

3.

AdvisorShares Psychedelics ETF

(1.3595%)

since

2025/08/29

4.

AdvisorShares Investments, LLC

(1.1098%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(1.0365%)

since

2025/07/31

6.

Geode Capital Management, LLC

(0.7247%)

since

2025/06/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6078%)

since

2025/07/31

8.

UBS Group AG

(0.5116%)

since

2025/06/30

9.

Citadel Advisors Llc

(0.3886%)

since

2025/06/30

10.

Fidelity Extended Market Index

(0.3118%)

since

2025/07/31

11.

BlackRock Inc

(0.2709%)

since

2025/06/30

12.

State Street Corp

(0.2149%)

since

2025/06/30

13.

Squarepoint Ops LLC

(0.1775%)

since

2025/06/30

14.

Marshall Wace Asset Management Ltd

(0.1404%)

since

2025/06/30

15.

iShares Micro-Cap ETF

(0.135%)

since

2025/08/31

16.

Two Sigma Investments LLC

(0.1323%)

since

2025/06/30

17.

Fidelity Total Market Index

(0.1306%)

since

2025/07/31

18.

Northern Trust Corp

(0.1203%)

since

2025/06/30

19.

Fidelity Nasdaq Composite Index

(0.0925%)

since

2025/07/31

20.

Fidelity Series Total Market Index

(0.0836%)

since

2025/07/31

21.

Spartan Extended Market Index Pool F

(0.0693%)

since

2025/07/31

22.

NT Ext Equity Mkt Idx Fd - L

(0.0643%)

since

2025/06/30

23.

Northern Trust Extended Eq Market Idx

(0.0643%)

since

2025/06/30

25.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0611%)

since

2025/07/31

26.

NT Ext Equity Mkt Idx Fd - NL

(0.0544%)

since

2025/06/30

27.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0423%)

since

2025/06/30

28.

Spartan Total Market Index Pool G

(0.0368%)

since

2025/07/31

29.

Extended Equity Market Fund K

(0.0207%)

since

2025/06/30

30.

Morgan Stanley - Brokerage Accounts

(0.0185%)

since

2025/06/30

31.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0181%)

since

2025/06/30

32.

Bank of America Corp

(0.0148%)

since

2025/06/30

33.

SBI Securities Co Ltd

(0.0143%)

since

2025/06/30

34.

Group One Trading, LP

(0.0131%)

since

2025/06/30

35.

1290 VT Micro Cap K

(0.0125%)

since

2025/07/31

36.

Wells Fargo & Co

(0.0084%)

since

2025/06/30

37.

Tower Research Capital LLC

(0.0049%)

since

2025/06/30

38.

State St US Extended Mkt Indx NL Cl C

(0.0039%)

since

2025/08/31

39.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0038%)

since

2024/12/31

40.

SIMPLEX TRADING, LLC

(0.0029%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.27

EPS Estimate

-0.52

EPS Difference

0.25

Surprise Percent

48.0769%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.